AL
Alma Yesodot Ltd.
KVSR | TA
Overview
Corporate Details
- ISIN(s):
- IL0011731457
- LEI:
- Country:
- Israel
- Address:
- HaBarzel 3, 6971005 Tel Aviv - Jaffa
- Website:
- https://www.almayesodot.co.il/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Kvasir focuses on developing innovative medical devices and diagnostic technologies.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
You have of free filing views remaining.
Upgrade for unlimited access.
Bulk Actions:
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-04-24 17:08 |
Regulatory News Service
Opening of Trading on April 27 2025-ALMA YESODOT B1
|
Hebrew (modern) | 118.8 KB | ||
| 2025-04-23 11:59 |
Regulatory News Service
Identifying Details of New Security-ALMA YESODOT B1
|
Hebrew (modern) | 87.5 KB | ||
| 2024-11-05 15:46 |
Regulatory News Service
Changes in the company's name and security, effective as of November 7, 2024
|
Hebrew (modern) | 108.5 KB | ||
| 2024-10-29 18:37 |
Regulatory News Service
The sector classification of the company will be changed, as of October 31, 202…
|
Hebrew (modern) | 121.3 KB | ||
| 2024-10-29 17:20 |
Regulatory News Service
Base price of 1 agora and unlimited price fluctuation
|
Hebrew (modern) | 90.8 KB | ||
| 2023-05-22 23:20 |
Report Publication Announcement
Frost and Sullivan is terminating coverage , following the completion of its co…
|
Hebrew (modern) | 174.5 KB | ||
| 2023-05-22 23:20 |
Pre-Annual General Meeting Information
Frost and Sullivan is terminating coverage , following the completion of its co…
|
Russian | 46.0 KB | ||
| 2023-03-23 21:00 |
Investor Presentation
Analysis update following financial report- price target is updated to NIS 22.7
|
English | 1.2 MB | ||
| 2023-03-23 21:00 |
Legal Proceedings Report
Analysis update following financial report- price target is updated to NIS 22.7
|
Russian | 71.0 KB | ||
| 2022-12-11 20:40 |
Investor Presentation
Analysis update following financial report- price target is updated to NIS 32.9…
|
English | 1.2 MB | ||
| 2022-12-11 20:40 |
Business and Financial Review
Analysis update following financial report- price target is updated to NIS 32.9…
|
Russian | 67.3 KB | ||
| 2022-08-30 20:47 |
Investor Presentation
Analysis update report ,target price is at 47.6NIS
|
English | 1.2 MB | ||
| 2022-08-30 20:47 |
Business and Financial Review
Analysis update report ,target price is at 47.6NIS
|
Russian | 63.9 KB | ||
| 2022-08-18 16:58 |
Investor Presentation
Presentation
|
English | 3.0 MB | ||
| 2022-08-18 16:58 |
Pre-Annual General Meeting Information
Presentation
|
Russian | 42.7 KB |
Automate Your Workflow. Get a real-time feed of all Alma Yesodot Ltd. filings delivered via API.
Market Data
Market Data Not Available
Last Price
Change / %
Market Cap
N/A
Volume
Day High
Day Low
52W High
52W Low
Financials & KPIs
No data available
Unlock Full Financials for Alma Yesodot Ltd.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Alma Yesodot Ltd. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
Company
Country
Ticker
View
Develops and supplies in vitro diagnostic solutions for human and veterinary markets.
United States of America
NNNN
United States of America
NNNN
Clinical-stage biotech developing an antidote for acute cannabinoid intoxication in ER patients.
United States of America
ANEB
United States of America
ANEB
Develops gene-based medicines like HGF gene therapy, DNA vaccines, and NF-kB decoys.
Japan
4563
Japan
4563
Develops & sells veterinary prescription & OTC medicines for professionals worldwide.
United Kingdom
ANCR
United Kingdom
ANCR
Develops, manufactures, and markets branded/generic drugs and OTCs for niche therapeutic areas.
United States of America
ANIP
United States of America
ANIP
Developing Annexin A5 protein to treat vascular, inflammatory, and cancerous diseases.
Sweden
ANNX
Sweden
ANNX
Developing C1q inhibitors for autoimmune, neurodegenerative, and ophthalmic diseases.
United States of America
ANNX
United States of America
ANNX
Develops and commercializes adult stem cell therapies and orphan drugs for medical conditions.
South Korea
065660
South Korea
065660
Develops and manufactures generic medicines and APIs, specializing in anti-infectives.
Romania
ATB
Romania
ATB
Developing novel C3 therapies for diseases in ophthalmology, nephrology, and hematology.
United States of America
APLS
United States of America
APLS